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Abstract
Objectives: We aimed to investigate the prognostic utility of the anatomical CABG
SYNTAX and logistic clinical SYNTAX scores for mortality after percutaneous coro-
nary intervention (PCI) in patients with prior coronary artery bypass grafts (CABG).
Background: The anatomical SYNTAX score evaluated the anatomical complexity of
coronary artery disease and helped predict the prognosis of patients undergoing PCI.
The anatomical CABG SYNTAX score was derived from the anatomical SYNTAX
score in patients with prior CABG, whilst the logistic clinical SYNTAX score was
developed by incorporating clinical factors into the anatomical SYNTAX score.
Methods: We calculated the anatomical CABG SYNTAX score and logistic clinical
SYNTAX score in 205 patients in the GLOBAL LEADERS trial. The predictive abilities
of these scores for 2-year all-cause mortality were evaluated.
Results: Using the median scores as categorical thresholds between low and high
score groups, the logistic clinical SYNTAX score was able to discriminate the risk of
2-year mortality, unlike the anatomical CABG SYNTAX score. The logistic clinical
SYNTAX was significantly better at predicting 2-year mortality, compared to the ana-
tomical CABG SYNTAX score, as evidenced by AUC values in receiver-operating
characteristic curve analysis (0.806 vs. 0.582, p < .001) and integrated discrimination
improvement (0.121, p < .001).
Conclusions: The logistic clinical SYNTAX score was superior to the anatomical
CABG SYNTAX score in predicting 2-year mortality.
K E YWORD S
coronary bypass grafts, drug eluting, percutaneous coronary intervention (PCI), risk
stratification, stent
1 | INTRODUCTION
The anatomical SYNTAX (Synergy between Percutaneous Coronary
Intervention with Taxus and Cardiac Surgery) score1 is recommended
to evaluate the anatomical complexity of coronary artery disease and
can also help predict medium-term prognosis in patients undergoing
percutaneous coronary intervention (PCI).2-4 The anatomical CABG
SYNTAX score, which takes into account the extent of revasculariza-
tion by bypass grafts, was proposed in 2012 for the patients who had
undergone coronary artery bypass graft (CABG) surgery.5 However,
the prognostic value of this specific score has not yet been further
evaluated in patients with prior CABG undergoing PCI.6
To enable individualized risk estimation for all-cause mortality
after PCI, the clinical SYNTAX score and logistic clinical SYNTAX
score was developed by combining the anatomical SYNTAX score and
clinical factors, and the logistic clinical SYNTAX score has been
recently updated and validated.7-10 The performance of the logistic
clinical SYNTAX score has been assessed in patients with left main
coronary artery disease and acute coronary syndromes,11,12 but not in
patients with prior CABG undergoing PCI.
We aimed to investigate and compare the prognostic perfor-
mance of the anatomical CABG SYNTAX score, clinical SYNTAX score
and logistic clinical SYNTAX score in predicting 2 years all-cause mor-
tality after PCI in patients with prior CABG using the GLOBAL
LEADERS trial database.13
2 | METHODS
2.1 | Study design and participants
The GLOBAL LEADERS trial (NCT01813435) was a prospective ran-
domized, open-label trial, designed to compare 23-month ticagrelor
monotherapy following one-month dual antiplatelet therapy and
12-month dual antiplatelet therapy followed by 12-month aspirin
monotherapy after PCI in a total of 15,991 all-comers patients.13
The anatomical SYNTAX score analysis was prespecified in the
protocol for the first 4,000 consecutive patients in the GLOBAL
LEADERS trial.14 Among the first 4 000 consecutive patients,
275 patients had a prior CABG. Of these 275 patients, one patient did
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not receive PCI, and coronary arteries and bypass grafts were not fully
assessed in 48 patients (e.g., native right coronary artery was not
assessed since a bypass graft to right coronary artery was patent).
Therefore, 226 had coronary angiograms for which the anatomical
CABG SYNTAX score could be calculated by an independent core lab
(ART, Academic Research Team, Rotterdam, The Netherlands),5 by
analysts unaware of the patient's treatment assignment or clinical
outcome.
The anatomical CABG SYNTAX score5 derived from Leaman
score15 was calculated by determining the standard anatomical SYN-
TAX score in the “native” coronary vessels (native SYNTAX score) and
deducting points based on the weighting of the diseased coronary
artery segment that have a functioning bypass graft anastomosed dis-
tally. Therefore, the anatomical CABG SYNTAX score could reflect
anatomical complexity and extent of revascularization, as well as the
anatomical SYNTAX score after PCI. An example of the calculation is
presented in Figure 1.
Of these 226 patients, at least one variable for the logistic clinical
SYNTAX score calculation was missing in 21 patients, thus, all baseline
characteristics for the updated logistic clinical SYNTAX score9 calcula-
tion including age, creatinine clearance (CrCl), left ventricular ejection
fraction (LVEF), body mass index (BMI), diabetes, peripheral vascular
disease (PVD), and SYNTAX-like characteristics, were available in
205 patients. SYNTAX-like characteristic was defined as unprotected
left main coronary artery disease and/or three vessel disease without
patency of grafts.
The clinical SYNTAX score is one of the historical and develop-
mental SYNTAX-derived scores and includes only three patient char-
acteristics: age, CrCl, and LVEF and was inspired by the ACEF
score.16-19 This score was calculated using the following formula; (the
anatomical CABG SYNTAX score) × (age/EF + 1 point for every
10 reduction in CrCl below 60 mL/min).7 In this calculation, a CrCl of
between 50 and 59 mL/min, 40 and 49 mL/min, 30 and 39 mL/min,
20 and 29 mL/min, 10 and 19 mL/min, and 0 and 9 mL/min would
receive 1, 2, 3, 4, 5, and 6 points, respectively.
The updated logistic clinical SYNTAX score in patients with prior
CABG was calculated using the following formula; 0.0187 × (the ana-
tomical CABG SYNTAX score) + 0.1667 × (SYNTAX-like char-
acteristic) + 0.0425 × (age) + 0.0174 × (90-CrCl) + 0.0522 × (50-EF)
+ 0.0312 × (BMI) + 0.57 × (PVD) + 0.3463 × (diabetes)−4.521.
All patients provided informed, written consent. The study com-
plied with the Declaration of Helsinki and Good Clinical Practices.
F IGURE 1 An example of the calculation of the anatomical CABG SYNTAX score. (a and b) Coronary segment-weighting derived from
Leaman score5,15 (a), and segment-weighting multiplication factors depending on severity of the lesion15 (b). These were used to calculate points
for deduction from the native SYNTAX score. (c) The native SYNTAX score was 41.5 due to left main and three-vessel disease (upper images). A
patent left internal mammary artery (LIMA) to left anterior descending artery (LAD) with no intervening obstructive disease (lower left image) led
to the deduction of 3.5 × 5 points (×5 segment-weighting due to occluded LAD) from the native SYNTAX score. A patent saphenous vein graft
(SVG) to left circumflex (LCX) with no intervening obstructive coronary disease (lower right image) led to 1 × 2 points (×2 segment-weighting due
to ischemic LCX) deduction. Therefore, the CABG SYNTAX score was 41.5–17.5–2 = 22 points. RCA, right coronary artery; LMCA, left main
coronary artery; an arrow indicates occlusion; arrow heads indicate stenosis [Color figure can be viewed at wileyonlinelibrary.com]
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2.2 | Endpoint
This study is a non-prespecified post-hoc analysis of the GLOBAL
LEADERS trial. The primary endpoint of this study was 2-year all-
cause mortality. The causes of death were classified to cardiovascular
death, noncardiovascular death and undetermined according to the
Academic Research Consortium (ARC)-2 definition.20 As defined in
the ARC-2 definition, undetermined death was classified as cardiovas-
cular death for end point determination. Patient-oriented composite
endpoint (POCE) of all-cause mortality, any stroke, any myocardial
infarction or any revascularization, net adverse clinical events (NACE)
of POCE or Bleeding Academic Research Consortium (BARC) grade
3 or 5 bleeding, and their components were also assessed with the
scores that have been specifically designed to predict all-cause
F IGURE 2 (a) Distribution of the anatomical CABG SYNTAX scores, clinical SYNTAX scores and logistic clinical SYNTAX scores. Scores are
shown as mean ± SD (median). (b) Cumulative incidence of all-cause mortality at 2 years [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 3 (a) Receiver-operating characteristic curves for the anatomical CABG SYNTAX score, clinical SYNTAX score and logistic clinical
SYNTAX score predicting 2-year all-cause mortality. p values were obtained using DeLong's test. (b) Calibration plot for the updated logistic
clinical SYNTAX score for 2-year all-cause mortality. Triangles represent two groups of patients with mean predicted probability and mean
observed all-cause mortality rate with 95% confidence interval. The distribution of patients is indicated with spike at the bottom of the graph,
stratified by outcomes (deaths above the x-axis and survivors below the x-axis) [Color figure can be viewed at wileyonlinelibrary.com]
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mortality.9,10 The survival status of the patients lost to follow up was
obtained through public civil registry and more than 99.95% of the
vital status at 2 years were available in the GLOBAL LEADERS trial.13
The vital status at 2 years were available in all 205 patients.
2.3 | Statistical analysis
Continuous variables were expressed as mean ± SD, and were com-
pared using Student's t test or Mann–Whitney U test. Categorical var-
iables were reported as numbers and percentages, and were
compared using chi square or Fisher's exact test as appropriate. The
cumulative event rates at 2 years were estimated by Kaplan–Meier
method and comparisons of outcomes were performed with log-rank
test. The all-cause mortality risk reclassification was assessed using
the net reclassification index (NRI). The predictive capability of the
anatomical CABG SYNTAX score, clinical STNTAX score and logistic
clinical SYNTAX score for the 2-year outcomes was assessed using
receiver-operating characteristic (ROC) curve analysis with area under
the curve (AUC). DeLong's test was used to analyze the differences
between AUC values of the anatomical CABG SYNTAX score, clinical
SYNTAX score and logistic clinical SYNTAX score and the
corresponding p values. The predictive value was also assessed by
integrated discrimination improvement (IDI). Agreement between
observed and predicted all-cause mortality was assessed by calibra-
tion plot. Two groups based on the updated logistic clinical SYNTAX
score were depicted in the calibration plot augmented by a locally
weighted scatterplot smoothing.21 Calibration-in-the-large (model
intercept) and calibration slope were evaluated by fitting the calcu-
lated linear predictor in all patients with all-cause mortality as the out-
come in the logistic regression model. Intercept of 0 and slope of
1 indicate perfect prediction. Negative and positive intercepts indicate
overestimation and underestimation, respectively. Brier score was
reported as an overall measure of performance, which ranges from
0 (perfect model) to 0.25 (non-informative model).21
A two-sided p value <.05 was considered statistically significant.
Analyses were performed using JMP Pro14 (SAS Institute Inc., Cary,
NC) and R version 3.6.0 (R Foundation for Statistical Computing,
Vienna, Austria).
3 | RESULTS
Patient characteristics, procedure characteristics, and medications at dis-
charge are shown in Tables 1–3, respectively. Distributions of the ana-
tomical CABG SYNTAX Scores, clinical STNTAX scores and logistic
clinical SYNTAX scores are shown in Figure 2a. Patients were divided
into two groups based on the median of the scores, as previously
reported5 (anatomical CABG SYNTAX score; ≦22 [low group, n = 105],
>22 [high group, n = 100], clinical SYNTAX score; ≦32.13 [low group,
n = 103], >32.13 [high group, n = 102] and logistic clinical SYNTAX
score; ≦0.372 [low group, n = 103], >0.372 [high group, n = 102]). The
rate of all-cause mortality at 2 years in the high anatomical CABG SYN-
TAX score group tended to be numerically higher than in the low ana-
tomical CABG SYNTAX score group, although they were not
significantly different (low = 6.7% vs. high = 12.0%, p = .19, Figure 2b).
On the other hand, there were significant differences in all-cause mor-
tality at 2-year between patients in the high versus low clinical SYNTAX
score group (low clinical SYNTAX score, 2.9%; high clinical SYNTAX
score, 15.7%; p = .0017) and those in the high versus low logistic clinical
SYNTAX score group (low logistic clinical SYNTAX score, 2.9%; high
logistic clinical SYNTAX score, 15.7%; p = .0016, Figure 2b). The logistic
clinical SYNTAX score tended to improve risk classification for the
2-year all-cause mortality, compared to the anatomical CABG SYNTAX
score (NRI, 0.221 [−0.068–0.511], p = .134) But there was no difference
between the logistic clinical SYNTAX score and clinical SYNTAX score
(NRI, 0.000 [−0.217–0. 217], p = 1.000). The ROC curves of the ana-
tomical CABG SYNTAX score, clinical SYNTAX score and logistic clinical
SYNTAX score for the 2-year all-cause mortality are shown in Figure 3a,
with significantly different AUC values of 0.582 (0.473–0.691), 0.721
(0.594–0.848), and 0.806 (0.714–0.899), respectively. This superior pre-
dictive ability of the logistic clinical SYNTAX score, compared to the
anatomical CABG SYNTAX score and clinical SYNTAX score, was also
demonstrated by the fact that IDI was 0.121 (0.052–0.190, p < .001)
and 0.052 (0.010–0.094, p = .017), respectively.
The updated logistic clinical SYNTAX score systematically under-
estimated 2-year all-cause mortality as demonstrated by the positive
TABLE 4 Causes of death
All patients
Logistic clinical
SYNTAX score
Causes of death n = 205 Low: n = 103 High: n = 102
Cardiovascular death 11/205 (5.37) 0/103 (0.00) 11/102 (10.8)
Noncardiovascular
death
7/205 (3.37) 2/103 (1.94) 5/102 (4.90)
Undetermined 1/205 (0.48) 1/103 (0.97) 0/102 (0.00)
Note: Variables were reported as numbers and percentages.
TABLE 5 Predictive ability of the logistic clinical SYNTAX score
for outcomes at 2 years
Outcomes at 2 years AUCs
All-cause death 0.806 (0.714–0.899)
Cardiovascular death 0.825 (0.717–0.934)
Stroke 0.668 (0.354–0.982)
Myocardial infarction 0.674 (0.487–0.861)
Revascularization 0.537 (0.430–0.645)
BARC 3 or 5 0.574 (0.369–0.779)
POCE 0.590 (0.496–0.685)
NACE 0.592 (0.500–0.685)
Abbreviations: AUC, area under the curve; BARC, bleeding academic
research consortium; POCE, patient-oriented composite endpoint; NACE,
net adverse clinical events.
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intercept (Figure 3b). Predicted probabilities of 2-year all-cause mor-
tality in the two groups were close to the ideal line. The Brier score of
the updated logistic clinical SYNTAX score for 2-year all-cause mortal-
ity was 0.076.
Definite cardiovascular deaths were more frequently observed
than noncardiovascular death (n = 11 [5.37%] vs. n = 7 [3.37%],
respectively, Table 4). Of note, no patient died from definite cardio-
vascular cause in low logistic clinical SYNTAX score group (Table 4),
and the predictive ability for the 2-year cardiovascular death of the
logistic clinical SYNTAX score was high (AUC: 0.825 [0.717–0.934],
Table 5).
Applying the logistic clinical SYNTAX score to the 2-year POCE
and NACE, the rates of POCE and NACE in 2 years was not signifi-
cantly different in low and high score groups (POCE: 23.3% vs. 32.7%,
p = .17; NACE: 24.2% vs. 34.6%, p = .14, respectively, Figure 4). The
AUC values for the 2-year POCE and NACE were 0.590
(0.496–0.685) and 0.592 (0.500–0.685), respectively. AUC values of
components of these composite endpoints are shown in Table 5.
4 | DISCUSSION
The main finding of this study is that compared to the anatomical
CABG SYNTAX score, the logistic clinical SYNTAX score is more
effective in predicting 2 years all-cause mortality after PCI in patients
with prior CABG. Furthermore, to the best of our knowledge, this
analysis is the first to evaluate the predictive value of the logistic clini-
cal SYNTAX score in patients with prior CABG.
Initially, we evaluated the performance of the anatomical CABG
SYNTAX score in predicting 2-year all-cause mortality. An anatomical
SYNTAX score ≦22 is generally accepted as a low score,22 and even
in patients with prior CABG, patients with a low anatomical CABG
SYNTAX score (≦22) tended to be at low risk for death (Figure 2b).
The anatomical CABG SYNTAX score in patients with prior CABG at
the time of PCI reflects on one hand the anatomical complexity of cor-
onary artery disease and on the other hand the extent and
functionality of the surgical revascularization previously performed,
but apparently cannot predict the 2 year vital prognosis of the
planned percutaneous revascularization post CABG. Therefore, this
score may not have a sufficient discriminative ability to predict 2 year
mortality. At variance with the anatomical CABG SYNTAX score, the
native anatomical SYNTAX score in patients with prior CABG reflects
the overall atherosclerosic burden but does not reflect the extent and
functionality of revascularization.
But, when patients were divided into two groups based on the
median of the native anatomical SYNTAX score in the present study
population (native anatomical SYNTAX score; ≦34 [low group,
n = 105], >34 [high group, n = 100], Figure S1a), there was no signifi-
cant difference in the rate of all-cause mortality at 2 years between
patients in the low and high native anatomical SYNTAX score groups
(low = 8.6% vs. high = 10.0%, p = .73, Figure S1b).
Patients with equivalent anatomical SYNTAX scores sometimes
have very different outcomes after revascularization, depending on
the presence of comorbidities.23 To overcome this limitation, com-
orbidities derived from surgical scores such as the ACEF16,17 or
EuroSCORE24 were incorporated into the anatomical SYNTAX score
(Clinical SYNTAX score7 or Global risk classification,25 respectively).
Following this, the logistic clinical SYNTAX score was developed,
updated and validated by combining the anatomical SYNTAX score
with clinical factors selected on the basis of logistic regression coeffi-
cients.8-10 Reflecting the logistic evolution of SYNTAX-derived scores,
the predictive value for the 2-year all-cause mortality of the logistic
clinical SYNTAX score was superior to the clinical SYNTAX score in
this study (Figure 3a). Although the updated logistic clinical SYNTAX
score systematically underestimated 2-year all-cause mortality in
patients with prior CABG, predicted probabilities of 2-year all-cause
mortality of the two groups were close to the identity line between
the predicted and observed mortality (Figure 3b).
The discriminative ability of the logistic clinical SYNTAX score for
2-year all-cause mortality in 3271 patients without prior CABG has
been already reported using the GLOBAL LEADERS database.10 Nota-
bly in this population, the prognostic value of the logistic clinical
F IGURE 4 Cumulative incidence of patient-oriented composite endpoint (POCE) and net adverse clinical events (NACE) at 2 years [Color
figure can be viewed at wileyonlinelibrary.com]
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SYNTAX score was much higher in patients with prior CABG (AUC,
0.806; Figure 3a) than in patients without (0.71).10
This differential performance can be partially explained by considering
the clinical characteristics and event rates in patients with and without
prior CABG. The rate of all-cause mortality in the present study (Figure 2b)
was 9.27%, whereas in the 3,271 patients without prior CABG in the vali-
dation cohort it was 2.66%.10 Patients with prior CABG also tended to be
older, have lower CrCl and LVEF, and had more comorbidities, such as dia-
betes mellitus and peripheral vascular disease, compared to those without
(Table 6).10 Furthermore, the rates of hypertension, hypercholesterolemia,
previous MI, previous PCI, previous stroke, and COPD were also higher in
patients with prior CABG, compared to those without (Table 6). Taken
together, the difference between the predictive values of the logistic clini-
cal SYNTAX score in patients with prior CABG compared to those without
might be largely dependent on major differences in clinical characteristics.
The predictive values of the logistic clinical SYNTAX score for POCE
and NACE were poor mainly due to the poor predictive value for revas-
cularization, although those for any stroke and myocardial infarction
were possibly helpful.26 The logistic clinical SYNTAX score was updated
to predict all-cause mortality in 6304 patients enrolled in seven contem-
porary coronary stent trials (SIRTAX, ARTS-II, STRATEGY, MULTI-
STRATEGY, LEADERS, SYNTAX, RESOLUTE All-Comers), and was not
accurate enough to predict outcomes other than mortality. However, of
note, in the present study, all definite cardiovascular deaths occurred in
the high logistic clinical SYNTAX score group (Table 4).
Pharmacological therapy and lifestyle changes for risk factor mod-
ification has been strongly recommended for secondary prevention
(Ia).22 In the SYNTAX trial started in 2005, optimal medical therapy
(OMT), defined as the combination of at least 1 antiplatelet,
angiotensin-converting-enzyme (ACE)-inhibitor/ angiotensin II recep-
tor blocker (ARB), beta-blocker, and statin was given in only 50.2% of
patients at the time of discharge after PCI.27 The GLOBAL LEADERS
trial was started in 2013. Regardless of the strong OMT recommenda-
tion, OMT was prescribed in 61.6% at discharge and even in the high
logistic clinical SYNTAX score patients, the rate of OMT was almost
the same and only 60% (Table 3). The logistic clinical SYNTAX score
can predict the individual mortality rate after PCI, and should be a
strong incentive to an aggressive adjunctive pharmacological treat-
ment and a closer monitoring of these patients at high risk.
In the future, further iterations of the logistic clinical SYNTAX
score may be needed due to improvement of mortality after PCI.
However, at present, the logistic clinical SYNTAX score has a high
predictive ability for 2-year all-cause mortality after PCI in patients
with prior CABG.
4.1 | Limitation
The present study is based on a non-prespecified post hoc analysis.
In view of the post hoc nature of the analysis, the results have to be
interpreted strictly as hypothesis-generating. The sample size
(n = 205) was small as a subanalysis of the large GLOBAL LEADERS
trial (n = 15,991). The number of deaths was 19 in the present study,
and external validation of a prognostic model generally requires a
minimum of 100 events.28 Therefore, the sample size might be insuf-
ficient to demonstrate the efficacy of the anatomical CABG SYNTAX
score. From the 275 patients with prior CABG included in the first
4,000 consecutive patients with corelab analysis of the SYNTAX
score (prespecified analysis), We excluded patients without anatomi-
cal CABG SYNTAX score and patients who had at least one missing
variable for the calculation of the logistic clinical SYNTAX score.
Therefore, selection bias might exist. The results need to be con-
firmed in dedicated large-scale trials. In terms of extent of revascu-
larization, the higher prognostic value of the post-PCI (residual)
CABG SYNTAX score in patients with prior CABG, compared to the
CABG SYNTAX score, has been previously reported.6 In the
GLOBAL LEADERS trial, only diagnostic angiograms for index PCI
were collected and post procedural angiograms were not available,
therefore, the predictivity of the residual CABG SYNTAX score could
not be evaluated. In addition, detailed information about prior CABG
surgery, such as the number of bypass grafts performed and the
completeness of revascularization, was missing in this trial which
enrolled patients exclusively for PCI.
5 | CONCLUSION
The logistic clinical SYNTAX score was superior to the anatomical
CABG SYNTAX score for predicting 2-year all-cause mortality
after PCI.
TABLE 6 Patient characteristics in patients with and without
prior CABG
Baseline characteristics
Present study
Patients with
prior CABG
Patients without
prior CABG
n = 205 n = 3,271 p value
Age (years) 68.8 ± 8.73 64.3 ± 10.5 <.001
Male 83.4% 76.4% .021
Body mass index (kg/m2) 28.2 ± 4.73 28.1 ± 4.46 .923
CrCl (ml/min) 81.0 ± 28.8 92.8 ± 32.7 <.001
LVEF (%) 52.3 ± 12.6 54.8 ± 10.7 .007
Hypertension 82.9% 69.7% <.001
Hypercholesterolemia 87.2% 66.9% <.001
Diabetes mellitus 36.6% 22.9% <.001
Previous MI 46.1% 20.9% <.001
Previous PCI 52.7% 28.6% <.001
Previous stroke 4.88% 2.33% .034
Established PVD 20.0% 6.14% <.001
COPD 9.76% 5.61% .020
Note: Continuous variables were expressed as mean ± SD, and categorical
variables were reported as percentages. CrCl, creatinine clearance; LVEF,
left ventricular ejection fraction; MI, myocardial infarction; PCI, percutane-
ous coronary intervention; PVD, peripheral vascular disease; COPD,
chronic obstructive pulmonary disease.
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